Sign In
Buy ATNM
$1.11
-0.0500 (-4.31%)
At Close: Jun 04, 2026
- The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis - Represen
Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved therapies totaling sales over $3.5 billio
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
06:15am, Friday, 15'th Mar 2024
Few stock sectors offer soar-or-sink possibilities like biotechnology stocks do. If you're in the market for an intriguing biotech pick and can manage high risk, take a look at Actinium Pharmaceutical
PanTera signs a second agreement for the supply of actinium-225
02:00am, Thursday, 14'th Mar 2024
PanTera's continues to deploy its strategy to become a market leader into the production and distribution of Ac225
Actinium's cyclotron produced Actinium-225 material has demonstrated radiochemical and radionuclidic purity identical to current gold-standard methods and has the potential to be significantly lower c
Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade)
06:21pm, Wednesday, 28'th Feb 2024
Actinium Pharmaceuticals, Inc. is a late-stage clinical biotechnology company focused on developing a radiopharmaceutical for the treatment of blood cancer. Positive data from the phase 3 SIERRA trial
- Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
01:37pm, Sunday, 25'th Feb 2024
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the
Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002)
NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)
07:00am, Monday, 08'th Jan 2024
BELOIT, Wis. & VANCOUVER, British Columbia--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225.
BELOIT, Wis. & CHESTER SPRINGS, Pa.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement.
- Two oral presentations and three poster presentations will highlight Iomab-B and Iomab-ACT CD45 targeted conditioning for bone marrow transplant and CAR-T cellular therapy NEW YORK , Jan
Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
06:08pm, Friday, 03'rd Nov 2023
Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. The main pipeline update is the presentation of find
Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?
07:02pm, Friday, 15'th Sep 2023
Actinium is making radiolabeled antibodies for use in hematologic cancers. Previously reported phase 3 trial results give a strong indicator of success at the regulatory level. No respect from the mar
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
02:16pm, Friday, 24'th Feb 2023
Actinium has lofty ambitions to change the landscape of leukemia treatment. But ATNM stock cratered this week on final-phase test results.
